Of the examined carcinomas, 62 (65%) were negative for ER-α and PR, whereas 16 (17%) showed immunostaining for both receptors; 16 (17%) were only positive for PR, and 2 (2%) were only positive for ER-α. This evidence concerns the gene ESR1 and carcinoma.